News Sentiment

NAUT sentiment intelligence

Nautilus Biotechnology Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 52 Balanced news tone 55 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 1.89 Week of 10 Jul 2026
Weighted tone 52/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

78/100 classification confidence.

Company focus 55

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

+9.2% over one week, -15.6% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Neutral

Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks

Market Reaction

Price moving ahead of tone

60/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 78/100 classification
One-week reaction 9.2% Price confirming higher
Trend fit Trend inactive -15.6% over four weeks
Fair value -12.4% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 11
Neutral 40
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 55
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Market source 11
TradingView 9
Stock Titan 6
marketscreener.com 6
TradingKey 5
simplywall.st 4
www.marketscreener.com 2
MarketBeat 2

Event Lens

What the news is about

Classified themes
Market update 28
Earnings 23
Balance sheet 1
Deals and strategy 1
Analyst action 1
Regulatory and legal 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 55
Sahm Direct company coverage

Nautilus Biotechnology And 2 Promising Penny Stocks To Consider

This article discusses three promising penny stocks for investors looking for growth opportunities in smaller companies: Nautilus Biotechnology (NAUT), Quantum-Si (QSI), and Butler National (BUKS). Nautilus and Quantum-Si are pre-revenue life sciences companies with strong cash p

Tone
Positive 61/100
Event
Balance sheet
Published
11 Jul 2026 14:10
Source
Sahm
Market source Direct company coverage

Nautilus Biotechnology to Announce Second Quarter 2026 Financial Results on July 28, 2026

Nautilus Biotechnology, Inc. (NASDAQ: NAUT) announced it will release its second-quarter 2026 financial results before market open on Tuesday, July 28, 2026. The company will host a webcasted conference call at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss these resu

Tone
Neutral 50/100
Event
Earnings
Published
09 Jul 2026 06:11
Source
Market source
scanx.trade Direct company coverage

Nautilus Biotechnology to announce Q2 2026 results on July 28

Nautilus Biotechnology, Inc. (NASDAQ: NAUT) will release its second-quarter 2026 financial results on July 28, 2026, before the market opens. Following the announcement, the company will host a conference call and webcast at 8:30 a.m. ET to discuss the results and provide a busin

Tone
Neutral 50/100
Event
Earnings
Published
08 Jul 2026 15:39
Source
scanx.trade
Stock Titan Direct company coverage

Nautilus Biotechnology sets July 28 call on Q2 results

Nautilus Biotechnology (NASDAQ:NAUT) will release its second-quarter 2026 financial results before market open on Tuesday, July 28, 2026. Management will host a webcast conference call at 5:30 a.m. PT / 8:30 a.m. ET to discuss results, business developments, and outlook. Historic

Tone
Positive 61/100
Event
Earnings
Published
08 Jul 2026 12:11
Source
Stock Titan
TradingView Direct company coverage

Price to sales forward of Nautilus Biotechnology, Inc. – NASDAQ:NAUT

This page displays the "Price to sales forward" metric for Nautilus Biotechnology, Inc. (NASDAQ: NAUT). It is a finance-related data point available on TradingView, specifically under the company's financial overview. The content provided appears to be a stub or a section of a la

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 06:39
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBIT forward of Nautilus Biotechnology, Inc. – NASDAQ:NAUT

This article provides access to the "Enterprise value to EBIT forward" for Nautilus Biotechnology, Inc. (NASDAQ: NAUT) via the TradingView platform. It appears to be a financial data page rather than an analytical article, indicating where users can find this specific financial m

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 06:10
Source
TradingView
Investing.com Nigeria Direct company coverage

Form 13D/A Nautilus Biotechnology For: 30 June By Investing.com

This article reports on a Form 13D/A filing for Nautilus Biotechnology concerning the period up to June 30th. It originates from Investing.com and was published on June 30, 2026, at 22:20. The filing likely pertains to significant ownership stakes and changes in beneficial owners

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 04:39
Source
Investing.com Nigeria
Stock Titan Direct company coverage

Andreessen Horowitz trims Nautilus (NAUT) stake in June 2026 block trade

Andreessen Horowitz-affiliated funds have filed an amended Schedule 13D for Nautilus Biotechnology, Inc. (NAUT), disclosing a reduction in their stake following a block trade on June 26, 2026, at $2.00 per share. Despite the sale, AH Bio Fund II and Andreessen Horowitz LSV Fund I

Tone
Neutral 50/100
Event
Deals and strategy
Published
01 Jul 2026 03:10
Source
Stock Titan
marketscreener.com Direct company coverage

Nautilus Biotechnology, Inc.(NasdaqCM: NAUT) added to Russell 2000 Growth Benchmark

Nautilus Biotechnology, Inc. (NasdaqCM: NAUT) has been added to the Russell 2000 Growth Benchmark. This inclusion is part of several recent additions to various Russell indices, reflecting increased recognition and market exposure for the biotechnology company. Nautilus Biotechno

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 04:39
Source
marketscreener.com
www.marketscreener.com Direct company coverage

Nautilus Biotechnology, Inc.(NasdaqCM:NAUT) added to Russell Small Cap Comp Growth Benchmark

Nautilus Biotechnology, Inc. (NasdaqCM: NAUT) has been added to the Russell Small Cap Comp Growth Benchmark. This inclusion is part of a series of additions to various Russell indices, including the Russell 2500 Growth, Russell 2000, and Russell Microcap indices. The company, foc

Tone
Positive 72/100
Event
Market update
Published
29 Jun 2026 21:40
Source
www.marketscreener.com
www.marketscreener.com Direct company coverage

Nautilus Biotechnology, Inc.(NasdaqCM:NAUT) added to Russell Small Cap Comp Value Benchmark

Nautilus Biotechnology, Inc. (NAUT) has been added to the Russell Small Cap Comp Value Benchmark, as announced on June 28, 2026. This inclusion is part of a series of additions to various Russell indexes, including Growth, 2500, 2000, 3000E, and Microcap benchmarks, reflecting th

Tone
Positive 71/100
Event
Market update
Published
29 Jun 2026 16:40
Source
www.marketscreener.com
marketscreener.com Direct company coverage

Nautilus Biotechnology, Inc.(NasdaqCM: NAUT) added to Russell Microcap Index

Nautilus Biotechnology, Inc. (NasdaqCM: NAUT) has been added to the Russell Microcap Index, a significant development for the life sciences company. This inclusion follows its additions to the Russell Microcap Value, Microcap Growth, Russell 2000 Growth, and Russell 3000E Growth

Tone
Positive 74/100
Event
Market update
Published
29 Jun 2026 05:40
Source
marketscreener.com
TradingKey Direct company coverage

Nautilus Biotechnology Inc (NAUT) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Nautilus Biotechnology Inc (NAUT), focusing on support, resistance, indicators, and moving averages. It highlights that the relevant support and resistance data have not been disclosed, and the technical indicators and moving averages

Tone
Negative 18/100
Event
Market update
Published
27 Jun 2026 02:38
Source
TradingKey
TradingView Direct company coverage

Nautilus Biotechnolgy, Inc. Actuals & Estimates (NASDAQ:NAUT)

This article provides financial actuals and estimates for Nautilus Biotechnology, Inc. (NASDAQ:NAUT), detailing its stock performance, analyst forecasts, and historical price movements. It includes information on current stock price, market capitalization, earnings reports, and a

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 13:38
Source
TradingView
Moomoo Direct company coverage

Press Release: Nautilus Biotechnology Reports First Quarter 2026 Financial Results

This press release details Nautilus Biotechnology's financial results for the first quarter of 2026. It will likely cover key financial metrics such as revenue, expenses, and net income for the period, along with any significant operational highlights or future outlook.

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 04:09
Source
Moomoo
TradingView Direct company coverage

NAUT Forecast — Price Target — Prediction for 2027

The article provides a forecast and price target for Nautilus Biotechnology, Inc. (NAUT) stock, noting that one analyst currently offers a 1-year price target of $4.00. It also includes key financial data, stock performance metrics, and responses to frequently asked questions abo

Tone
Neutral 50/100
Event
Analyst action
Published
26 Jun 2026 01:10
Source
TradingView
Stock Titan Direct company coverage

Nautilus Biotechnology (NAUT) grants 45,000 stock options to director

Nautilus Biotechnology, Inc. (NAUT) granted 45,000 stock options to director Karen Akinsanya on June 18, 2026, as part of her compensation. The options have an exercise price of $2.28 per share and expire on June 18, 2036. They will vest in equal monthly installments over 12 mont

Tone
Neutral 50/100
Event
Market update
Published
23 Jun 2026 00:11
Source
Stock Titan
Stock Titan Direct company coverage

[Form 4] Nautilus Biotechnology, Inc. Insider Trading Activity

Nautilus Biotechnology director Matthew S. McIlwain received a grant of 45,000 stock options, with an exercise price of $2.28 per share and an expiration date of June 18, 2036. These options will vest over time, with one-twelfth vesting monthly, conditional on his continued servi

Tone
Neutral 50/100
Event
Market update
Published
22 Jun 2026 20:39
Source
Stock Titan
Stock Titan Direct company coverage

Director at Nautilus (NAUT) granted 45,000 stock options vesting monthly

Nautilus Biotechnology director Melissa B. Epperly was granted 45,000 stock options with an exercise price of $2.28 per share, expiring on June 18, 2036. These options vest in equal monthly installments over 12 months, contingent on her continuous service as a "Service Provider"

Tone
Neutral 50/100
Event
Market update
Published
22 Jun 2026 20:39
Source
Stock Titan
Stock Titan Direct company coverage

Nautilus Biotechnology (NAUT) investors approve directors, auditor and annual Say on Pay

Nautilus Biotechnology, Inc. (NAUT) held its 2026 annual meeting where shareholders approved the election of Class II directors Parag Mallick and Farzad Nazem, ratified PricewaterhouseCoopers LLP as the independent auditor for 2026, and gave advisory approval to the 2025 executiv

Tone
Neutral 50/100
Event
Regulatory and legal
Published
18 Jun 2026 19:40
Source
Stock Titan
TradingKey Direct company coverage

Nautilus Biotechnology Inc (NAUT) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for Nautilus Biotechnology Inc (NAUT), noting that relevant data for key metrics like P/E, P/B, P/S, and P/CF ratios have not yet been disclosed by the company. It briefly shows the current stock price, market cap, and indicates that the

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 20:40
Source
TradingKey
TradingKey Direct company coverage

Nautilus Biotechnology Inc (NAUT) Institutional Confidence

This article provides details on the institutional confidence in Nautilus Biotechnology Inc (NAUT), including its stock price, market cap, and a breakdown of its TradingKey Stock Score dimensions. It lists significant institutional shareholders and their shareholdings, offering i

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 17:39
Source
TradingKey
TradingKey Direct company coverage

Nautilus Biotechnology Inc (NAUT) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Nautilus Biotechnology Inc (NAUT), including analyst ratings and target prices. Two analysts rate NAUT as a "Strong Buy," with a target price of $2.50, representing an 84.33% upside. The company's recent EPS was -$0.11 against an exp

Tone
Neutral 50/100
Event
Earnings
Published
17 Jun 2026 16:39
Source
TradingKey